Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 1, 2011, Pages 157-163

  Doggrell, Sheila A ^a   Christensen, Anne Marie ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Chronic myeloid leukaemia; Clinical trials; Dasatinib; Imatinib; Nilotinib

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTICENTER STUDY (TOPIC); MUSCLE SPASM; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRURITUS; QT INTERVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 78650476029     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.534780     Document Type: Article

References (23)

1. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL mutation or amplification. Science 2001;293:876-80
2. Rosti G, Castagnetti F, Gugliotta G, et al. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a head-to-head comparison. Leuk Lymphoma 2010;51:583-91
3. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatanib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
5. Wiesberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
6. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant or intolerant of imatinib. Clin Cancer Res 2008;14:5325-31
7. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2594-6
8. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-46
9. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-8
10. Cortes JE, Jones D, OBrien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7
11. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methylphenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-caboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumour activity in preclinical assays. J Med Chem 2004;47:6658-61
12. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/ tasigna.pdf Tasigna Highlights of prescribing information. [Accessed 23 September 2010]
13. Available from: http://www.rxlist.com/ sprycel-drug.htm Sprycel. [Accessed 13 October 2010]
14. Kantarijan H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistance to imatinib at a dose of 400 to 600 milligrams daily; two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-47
15. Cortes JE, Jones D, OBrien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
16. Manley PW, Stiefl N, Cowan-Jacob S, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Biorg Med Chem 2010;18:6977-86
17. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphic chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;11:2289-308
18. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-42
19. Johnson FM, Agrawal S, Burris H, et al. Phase I pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumours. Cancer 2010;116:1582-91
20. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
21. Breccia M, Santopietro M, Loglisci G, et al. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. Leuk Res 2010;34:e224-5
22. Available from: http://www.fda.gov/ AboutFDA/CentersOffices/CDER/ ucm216218.htm FDA Nilotinib (Tasigna) [Accessed 23 September 2010]
23. Available from: http://www.thestreet. com/story/10803115/sprycel174- dasatinib-receives-fda-priority-review-forthe- treatment-of-adult-patients- withnewly- diagnosed-chronic-myeloidleukemia- cml-in-chronic-phase.html SPRYCEL (dasatinib) receives FDA priority review for the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. [Accessed 23 September 2010]